TP53 rs1042524: Understanding the Arg72Pro Variant
The rs1042524 variant, commonly known as the Arg72Pro polymorphism, is a functional change in the TP53 gene. It is associated with differences in how cells undergo apoptosis and has been studied for its potential role in susceptibility to various cancer types.
What each genotype means
Arginine homozygous genotype
This genotype encodes the Arginine (Arg) variant at codon 72 of the TP53 protein. Research into this common polymorphism has produced mixed results regarding its influence on cancer susceptibility, with some studies suggesting it may have different apoptotic capabilities compared to the Proline variant. Because findings are often inconsistent across different populations and cancer types, this genotype is considered a normal variation rather than a diagnostic indicator.
This is the most common genotype in many populations, though frequencies vary significantly by ancestry.
Arginine and Proline heterozygous genotype
This genotype indicates you carry one copy of the Arginine (Arg) allele and one copy of the Proline (Pro) allele at codon 72 of the TP53 gene. Scientific literature has extensively studied this polymorphism for potential associations with cancer risk, but results remain controversial and often contradictory. It is currently viewed as a common genetic variation that does not provide a clear clinical prediction for individual health outcomes.
This heterozygous state is frequently observed globally, with the Pro allele appearing in approximately 20% to 40% of individuals depending on their ancestral background.
Proline homozygous genotype
This genotype encodes the Proline (Pro) variant at codon 72 of the TP53 protein. While some studies have explored whether this variant influences susceptibility to specific malignancies, the evidence is limited and often conflicting across different ethnic groups. This genotype is widely recognized as a common polymorphism and is not considered a definitive marker for disease risk.
This genotype is less common than the Arginine homozygous state, with the Pro allele frequency typically ranging between 20% and 40% in most populations.
What is the rs1042524 Variant?
The rs1042524 variant is a single nucleotide polymorphism (SNP) located within the TP53 gene on chromosome 17. Specifically, this variant results in a change at codon 72 of the p53 protein, where the amino acid arginine (Arg) is replaced by proline (Pro). Because this change occurs in a functional region of the protein, researchers have long investigated whether this substitution alters the protein's ability to perform its duties. The p53 protein is a critical tumor suppressor, often referred to as the 'guardian of the genome' because it monitors cellular health and triggers repair or cell death when DNA damage is detected. Because rs1042524 sits in a region involved in the protein's ability to induce apoptosis, or programmed cell death, scientists have hypothesized that the Arg and Pro versions of the protein might function with different efficiencies, potentially influencing how an individual's cells respond to stress or damage over a lifetime.
The Role of the TP53 Gene
The TP53 gene provides instructions for making the p53 protein, which acts as a tumor suppressor. This protein is essential for maintaining genomic stability by preventing cells from dividing too rapidly or in an uncontrolled manner. When a cell experiences stress—such as DNA damage, hypoxia, or oncogene activation—p53 is activated to regulate the expression of various target genes. Depending on the severity of the damage, p53 can initiate cell cycle arrest to allow time for DNA repair, or it can trigger apoptosis to eliminate cells that are too damaged to be safely repaired. By removing potentially dangerous cells, p53 helps prevent the development of tumors. Because of its central role in these protective pathways, variations in the TP53 gene are of significant interest in oncology research. While most research focuses on rare, highly pathogenic mutations that cause hereditary cancer syndromes like Li-Fraumeni syndrome, common polymorphisms like rs1042524 are studied for their more subtle, population-level effects on cancer risk.
Research and Evidence Strength
Research into rs1042524 has produced a vast, yet often conflicting, body of literature. Numerous studies have examined whether the Arg or Pro allele is associated with an increased risk of specific cancers, including colorectal, lung, and gastric cancers. Some meta-analyses have suggested that the Pro variant may contribute to cancer risk in specific populations, such as Asian cohorts, while other studies have found no significant association or even contradictory results in different ethnic groups. The evidence for this variant is considered limited because the associations are often weak, inconsistent across different studies, and highly dependent on the specific population being analyzed. It is important to recognize that cancer is a complex, multifactorial disease influenced by a combination of genetics, environment, and lifestyle. Consequently, a single SNP like rs1042524 is unlikely to be a primary driver of disease on its own, and current scientific consensus does not support using this variant as a standalone diagnostic or predictive tool for cancer risk.
Population Frequency
The frequency of the rs1042524 alleles varies significantly across different global populations. The Pro allele frequency generally ranges from approximately 0.20 to 0.40, depending on the ancestral background of the group being studied. Because of this variation, the distribution of the GG, GC, and CC genotypes (representing the Arg/Arg, Arg/Pro, and Pro/Pro pairings) is not uniform worldwide. Researchers often account for these ancestral differences when conducting genetic association studies to ensure that observed correlations are not simply due to population stratification. Understanding these frequency differences is a standard part of genomic research, as it helps scientists determine whether a specific genetic association is consistent across diverse groups or if it is unique to a particular geographic or ethnic population.
What This Information Means for You
If you have received information about your rs1042524 genotype, it is important to view it within the context of current scientific understanding. This variant is a common polymorphism, not a rare, high-risk mutation. Having one genotype over another does not constitute a medical diagnosis, nor does it provide a definitive prediction about your future health. Because the evidence linking this variant to specific health outcomes is limited and often inconsistent, it is not currently used in routine clinical practice to guide medical decisions or cancer screening. You should not make any changes to your health management or lifestyle based solely on this genetic information. If you have concerns about your personal or family history of cancer, the most appropriate step is to consult with a healthcare professional or a certified genetic counselor. They can help you interpret your overall risk profile, which includes factors far more significant than a single SNP, such as family history, environmental exposures, and clinical screenings.
How common is this variant?
The Pro allele frequency for rs1042524 typically ranges between 0.20 and 0.40, with significant variation observed across different global ancestral populations.
Frequently asked questions
Is rs1042524 a cause of cancer?
No, rs1042524 is a common genetic polymorphism, not a direct cause of cancer. While some studies have explored its association with cancer risk, the evidence is limited and inconsistent, and it is not considered a primary driver of disease.
Should I get tested for the TP53 Arg72Pro variant?
There is no clinical recommendation to test for this variant. Because it does not provide actionable medical information, it is not used in standard clinical diagnostics or cancer risk assessment.
Does my genotype mean I need more frequent cancer screenings?
No. Your genotype for this variant does not change the standard medical guidelines for cancer screening. You should follow the screening recommendations provided by your doctor based on your age, sex, and family history.
Can I change my risk associated with this variant?
Because this variant is not a definitive cause of disease, the concept of 'changing your risk' does not apply. Maintaining a healthy lifestyle, such as avoiding tobacco and following recommended health screenings, is the best way to manage general cancer risk.
Sources & further reading
Educational information only, last refreshed 9/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1042524?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TP53
Pathogenic missense variant (p.Arg248Gln) associated with Li-Fraumeni syndrome.
Functional 3' UTR polyadenylation signal polymorphism altering TP53 transcription termination, showing population-specific baseline carrier frequencies across global groups.
Pathogenic hotspot variant (p.Arg273His) in TP53 predisposing carriers to early-onset sarcomas, breast cancers, and leukemias.
Li-Fraumeni syndrome missense variant (p.Arg248Trp) causing loss of tumor suppressor function and multi-cancer predisposition.
Synonymous and regulatory variant in linkage with TP53 codon 72 that modulates blastocyst implantation competence and the risk of recurrent implantation failure.
3' UTR hypomorphic variant in TP53 that impairs proper polyadenylation and significantly confers elevated risk for basal cell carcinoma, glioma, and other cancers.